Skip to content
DataLookout
Menu

NCT07949760

WOKVAC Vaccine to Prevent Brain Metastases in Metastatic HER2 Positive Breast Cancer, SHIELD Trial

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Incidence of brain metastasis
Timeframe: From the date of first vaccination to the first clinically detected, radiographically confirmed brain metastasis, assessed up to 5 years

Secondary (3)

Change in interferon gamma
Cytotoxic T-cell response
Epitope spreading

Arms and interventions

Treatment (WOKVAC, sargramostim)Experimental

Patients receive WOKVAC mixed with sargramostim ID at months 1, 2, 3, 6, 12, and 24 in the absence of brain metastases or unacceptable toxicity. Patients may also receive tetanus-diptheria immunization with first vaccine per standard of care. Additionally, patients undergo blood sample collection and magnetic resonance imaging (MRI) or computed tomography (CT) at baseline and possibly at later study milestones.

Biologicals: pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine, Sargramostim, Tetanus and Diphtheria Toxoids Adsorbed

Procedures: Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection

Sites

1 site in 1 country

  • Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States